ALAMEDA Alliance FOR HEALTH	Alameda Alliance for Health FORMULARY UPDATE **Effective 11/01/2026, unless indicated below under Committee Actions.**

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions

The P&T Committee reviewed the efficacy, safety, cost, and utilization profiles of the following therapeutic categories and drug monographs at the September 15,2026 meeting:

Therapeutic/Monograph Class Reviews	
• Chelating agents Class Review • Hepatitis B agents Class Review • Intranasal steroids Class Review	• Pancreatic Enzymes Class Review • Pneumococcal Vaccines Class Review • Respiratory Aids and Devices Class Review

The P&T Committee approved the following modifications to the formulary for the Alliance's Group Care programs.

Generic//Biosimilar Name & Strength/Dosage Form	**Brand Name**	**Committee Actions**
filgrastim-laha Injection Solution Prefilled Syringe 480 MCG/0.8ML	Filkri Injection Solution Prefilled Syringe 480 MCG/0.8ML	Add to Formulary with Prior Authorization (F-PA)
filgrastim-laha Injection Solution Prefilled Syringe 300 MCG/0.5ML	Filkri Injection Solution Prefilled Syringe 300 MCG/0.5ML	Add to F-PA
orforglipron-Weight Management Oral Tablet 0.8 MG	Foundayo Oral Tablet 0.8 MG	Add to Formulary with Prior Authorization (F-PA) Quantity Limit (QL) (30 tablets/30 days)
orforglipron-Weight Management Oral Tablet 2.5 MG	Foundayo Oral Tablet 2.5 MG	Add to F-PA-QL (30 tablets/30 days)
orforglipron-Weight Management Oral Tablet 5.5 MG	Foundayo Oral Tablet 5.5 MG	Add to F-PA-QL (30 tablets/30 days)
orforglipron-Weight Management Oral Tablet 9 MG	Foundayo Oral Tablet 9 MG	Add to F-PA-QL (30 tablets/30 days)
orforglipron-Weight Management Oral Tablet 14.5 MG	Foundayo Oral Tablet 14.5 MG	Add to F-PA-QL (30 tablets/30 days)
orforglipron-Weight Management Oral Tablet 17.2 MG	Foundayo Oral Tablet 17.2 MG	Add to F-PA-QL (30 tablets/30 days)
resmetirom Oral Tablet 60 MG	Rezdiffra Oral Tablet 60 MG	Add to F-PA-QL (30 tablets/30 days)
resmetirom Oral Tablet 80 MG	Rezdiffra Oral Tablet 80 MG	Add to F-PA-QL (30 tablets/30 days)
resmetirom Oral Tablet 100 MG	Rezdiffra Oral Tablet 100 MG	Add to F-PA-QL (30 tablets/30 days)
doravirine-Islatravir Oral Tablet 100-0.25 MG	Idvynso Oral Tablet 100-0.25 MG	Add to F-PA-QL (30 tablets/30 days)
trientine HCl Oral Capsule 250 MG	Syprine Oral Capsule 250 MG	Update to Formulary (F)

PRIOR AUTHORIZATION GUIDELINE UPDATES	
Iron-chelating Agents	Hepatitis C Medications
Dronabinol	Duvyzat
White Blood Cell Stimulators	Anti-Obesity Medications
Constipation agents	Injectable/Infusible Bone-Modifying Agents for Oncology Indications
Immunizations	Injectable/Infusible Agents for Osteoporosis and Paget's Disease
Medications for the treatment of Multi-Drug Resistant Tuberculosis	Pulmonary Biologics for Respiratory and Eosinophilic Conditions
Palforzia	Agents for Primary Biliary Cholangitis
Hepcludex	

PRIOR AUTHORIZATION GUIDELINES REVIEWED (NO UPDATES)	
Physician Administered Medication (PAD)/ Medical Benefit Guidelines	Multaq (dronedarone)
Off-label uses	Erythropoiesis-Stimulating Agents
Safety Edit Exception	Drugs for Gender Dysphoria For Less Than 21 Years Old
Quantity Limit Exception	Drugs for Gender Dysphoria For At Least 21 Years Old
Antibiotic Eye Medications	Lidocaine Patch
Antiemetics	Mesalamine
Nuedexta (dextromethorphan/quinidine)	Corticosteroids for Ulcerative Colitis and Crohn's disease
Cartilaginous Repair Agents	Atovaquone-proguanil (Malarone)
Memantine ER (Namenda XR)	Intranasal Steroids
Ophthalmic Anti-inflammatory Immunomodulators	Scabicides and Pediculicides
Penicillamine (Depen, Cuprimine), Trientine HCl (Syprine) for Wilson's disease	Rifamycin Antibiotics
Vancomycin	Topical Acne Agents
Viberzi (eluxadoline)	Alosetron (Lotronex)
Rifabutin (Mycobutin)	Vowst
Tranexamic acid (Lysteda)	Rho Kinase Inhibitors
Moxifloxacin Oral Tablet	Xolremdi
Santyl Ointment	Anti-Parkinson's Agents for OFF Episodes
Topical Antibiotics	Ctexli
Vykat XR	

For questions, please contact the Alliance's Pharmacy Services department at: (510) 747-4541.